THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics, Inc. (NasdaqGM:RPRX) (“Repros” or the “Company”) today announced that it entered into the Sixth Amendment to its Agreement (the “Agreement”) with the National Institutes of Health (“NIH”) (the “Amendment”) relating to the Company’s lead product Proellex. The Amendment clarified that certain cancers related to the human reproductive system are within the scope of the licensed field, amended the development and commercialization benchmarks that the Company is required to meet under the Agreement and added or modified certain milestone payments due to NIH on the achievement of certain benchmarks.
